October 29, 2025 — Savara Inc. (Nasdaq: SVRA) has announced the commencement of an underwritten public offering of common stock shares and pre-funded warrants for certain investors. The offering’s completion, size, and terms are subject to market conditions.
Savara intends to use the offering proceeds for general corporate purposes, including clinical development funding for MOLBREEVI*, pursuing regulatory approval, investing in commercialization infrastructure and supply, preparing for commercial launch in the U.S. and EU, and covering general and administrative expenses. Underwriters may also purchase up to an additional 15% of offered shares and warrants.
Jefferies, Piper Sandler, and Guggenheim Securities are joint book-running managers, with Oppenheimer & Co. as lead manager and Citizens Capital Markets and H.C. Wainwright & Co. as co-managers.
The shares and warrants are offered under an existing shelf registration statement (File No. 333-279274) filed with the SEC. A preliminary prospectus supplement with offering terms will be filed with the SEC.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.
Copies of the preliminary prospectus supplement and accompanying prospectus relating to the proposed offering may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, by telephone at (800) 747-3924 or by email at prospectus@psc.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com. An electronic copy of the prospectus supplement and accompanying prospectus relating to the offering will be available on the SEC website at www.sec.gov.
Savara cautions that forward-looking statements involve risks and uncertainties. The company undertakes no obligation to update such statements.
Source: Savara Inc.
